Respiratory drugs get green light for PBS listing

Several new drug products for asthma, COPD and cystic fibrosis have been recommended for PBS listing  by the Pharmaceutical Benefits Advisory Committee.

The long-acting anticholinergic bronchodilator aclidinium bromide has been recommended for a restricted benefit PBS listing for treatment of COPD on the basis that the drug is non-inferior in terms of comparative effectiveness and comparative safety to tiotropium.

At its March meeting, the PBAC recommended